Figure 1 - available via license: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Content may be subject to copyright.
Scatter plot of anti-Spike IgG titers before mRNA-1273 booster and time since most recent "virus exposure"
Source publication
Background: The inactivated whole-virus vaccine CoronaVac (SinoVac) is the COVID-19 vaccine most administered worldwide. However, data on its immunogenicity and reactogenicity to heterologous boosting with mRNA vaccines are lacking.
Methods: In a cohort of hospital staff in Jakarta, Indonesia, who received two-dose CoronaVac six months prior (media...
Contexts in source publication
Context 1
... IgG titers varied from 0.97 BAU/mL to 21 466 BAU/mL (4.35 log10 range), and were higher overall in previously infected than in naïve participants (Figure 1 and Figure S1). Preboost IgG titers correlated negatively with the time since the most recent documented "virus ...
Context 2
... IgG titers varied from 0.97 BAU/mL to 21 466 BAU/mL (4.35 log10 range), and were higher overall in previously infected than in naïve participants (Figure 1 and Figure S1). Preboost IgG titers correlated negatively with the time since the most recent documented "virus ...
Similar publications
Background
In response to SARS-CoV-2 mutations and waning antibody levels after two-dose inactivated vaccines, we assessed whether a third dose of recombinant protein subunit vaccine (ZF2001) boosts immune responses.
Methods
An open-label single-center non-random trial was conducted on people aged 18 years and above at five sites in China. All par...
Citations
... Countries with a high vaccination coverage, including some in the Middle East, initiated boosting programs with heterologous vaccines even before a solid scientific basis for the procedure was published [1]. Recent evidence suggests that heterologous messenger RNA (mRNA) boosters are highly immunogenic and relatively safe [2,3]. The Moderna COVID-19 vaccine (mRNA-1273) was approved during the initial phase of emergency-use authorization in 87 countries as the primary vaccine and is being used as a booster vaccine in several countries, including Indonesia [4]. ...
Coronavirus disease 2019 (COVID-19) has been extensively researched, particularly with regard to COVID-19 vaccines. However, issues with logistics and availability might cause delays in vaccination programs. Thus, the efficacy and safety of half-dose heterologous mRNA should be explored. This was an open-label observational study to evaluate the immunogenicity and safety of half-dose mRNA-1273 as a booster vaccine among adults aged >18 years who underwent a complete primary SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination regimen with CoronaVac® and ChAdOx1-S. Adverse events (AEs), seropositivity rate, seroconversion, geometric mean titer (GMT) of SARS-CoV-2 antibodies, neutralizing antibodies, and T cells (CD4+ and CD8+) specific for SARS-CoV-2 were analyzed. Two hundred subjects were included in the final analysis, with 100 subjects in each priming vaccine group. Most of the AEs were mild, with systemic manifestations occurring between 1 and 7 days following vaccination. A significant difference was observed in the GMT and seropositivity rate following booster dose administration between the two groups. CD8+/CD3+, IFN (interferon)-producing CD8+, and TNF (tumor necrosis factor)-producing CD8+ cells showed significant increases in both groups. The administration of the half-dose mRNA-1273 booster is safe and effective in increasing protection against SARS-CoV-2 infection.
... This is in line with research conducted by Richards et al. (15) where there was no significant difference in antibody titer between subjects under 50 years old and those over 50 years old who received either Pfizer or Moderna vaccine. Sinto et al. (16) also found in their study that there was no significant correlation between antibody titer and age (16). A study conducted by Bates et al. (17) also showed no significant age-related trend among participants. ...
... This is in line with research conducted by Richards et al. (15) where there was no significant difference in antibody titer between subjects under 50 years old and those over 50 years old who received either Pfizer or Moderna vaccine. Sinto et al. (16) also found in their study that there was no significant correlation between antibody titer and age (16). A study conducted by Bates et al. (17) also showed no significant age-related trend among participants. ...
... Our study shows that antibody titer was not significantly correlated with gender. This result is also supported by the studies by Richards et al., (15), Sinto et al., (16) and Cucunawangsih et al. (18) who found in their studies that gender did not have a significant relationship with antibody titer. However, another study conducted by Ibarguengoitia et al. (13) showed a difference in terms of patient gender with significant correlations, since females had higher antibody titers. ...
p> Objective . The longevity of vaccine effectiveness and antibody titer after the Moderna mRNA COVID-19 vaccination booster in healthcare workers in Indonesia is not known.
Materials and Methods . We performed a prospective observational study of healthcare workers at the Universitas Indonesia Hospital after Moderna mRNA COVID-19 booster vaccination. An Immunology Analyzer with Chemiluminescence Immunoassay (CLIA) test was used to examine Anti SARS-CoV-2 S-RBD levels. Antibody levels were classified into two systems (3 categories, and 2 categories).
Results . There were 31 male subjects (75.6%), 33 subjects (80.5%) aged 25-39 years, 17 subjects (41.5%) with overweight BMI, 35 subjects (85.4%) without comorbidities, and 29 subjects without previous history of COVID-19 infection (70.7%) who had antibody titer >1000 AU/ml. There were 27 subjects (65.9%) who had a booster shot ≥6 months after the second vaccination with antibody titer >1000 AU/ml. In this study, there was no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination.
Conclusion . There is no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination</p
... Investigadores de Indonesia han reportado los resultados de un ensayo clínico de una vacunación heteróloga para la tercera dosis con Moderna-NIH (Spikevax) después de dos dosis con Sinovac (CoronaVac). El ensayo examinó la inmunogenicidad y reactogenicidad de la dosis de refuerzo [18]. ...
Las vacunas contra el SARS-CoV-2 se han desarrollado y desplegado rápidamente a nivel mundial como una medida para combatir la COVID-19. Se ha demostrado que estas vacunas confieren una protección significativa, pero ha habido informes del deterioro temporal en los títulos de anticuerpos neutralizantes. Además, se han identificado variantes del SARS-CoV-2 (e.g. ómicron) con diversos grados de resistencia a los anticuerpos. Estos dos factores pueden sugerir que vale la pena considerar una dosis de refuerzo, especialmente en personas inmunodeprimidas. Como alternativa para la mejora de la respuesta inmunitaria, se ha propuesto una estrategia de refuerzo heteróloga para provocar respuestas inmunitarias tanto humorales como mediadas por células que podrían conducir a una inmunidad robusta, amplia y duradera. En esta revisión, se informan algunos resultados de ensayos clínicos de dosis de refuerzo heteróloga contra la COVID-19.
Globally, the vaccine has been determined as one of the principal policies to tackle the COVID-19 pandemic. However, some vaccinated individuals with two complete doses of inactivated experienced SARS-CoV2 infection, including the healthcare workers (HCWs). This threat led to the emergent need for a vaccine booster with different types of platforms aiming to enhance immunity from the Omicron variant. We conducted a literature study on the concept of heterologous compared to homologous vaccines in COVID-19 vaccination. We obtained 22 studies about COVID-19 booster vaccines. Referring to seven of them, we compared and distinguished between heterologous and homologous vaccines. We then reported the literature review according to PRISMA guideline. The study demonstrated qualitatively that heterologous vaccinations boosted antibody receptor binding domain, neutralizing antibody, and spike-specific Th1 type T cell responses and had an impact on omicron infection when compared to homologous vaccines. In conclusion, heterologous, mRNA based vaccine, predominantly induces cellular and humoral responses better than the homologous vaccine. This increased immune response is expected to provide profound immunity against the Omicron.
A strong and effective COVID-19 and future pandemic responses rely on global efforts to carry out surveillance of infections and emerging SARS-CoV-2 variants and to act accordingly in real time. Many countries in Southeast Asia lack capacity to determine the potential threat of new variants, or other emerging infections. Funded by Wellcome, the Southeast Asia initiative to combat SARS-CoV-2 variants (SEACOVARIANTS) consortium aims to develop and apply a multidisciplinary research platform in Southeast Asia (SEA) for rapid assessment of the biological significance of SARS-CoV-2 variants, thereby informing coordinated local, regional and global responses to the COVID-19 pandemic. Our proposal is delivered by the Vietnam and Thailand Wellcome Africa Asia Programmes, bringing together a multidisciplinary team in Indonesia, Thailand and Vietnam with partners in Singapore, the UK and the USA. Herein we outline five work packages to deliver strengthened regional scientific capacity that can be rapidly deployed for future outbreak responses.
